Quote:
Originally Posted by jfman
https://ec.europa.eu/info/live-work-...blic-health_en
The EU look in a good position to me. I hope they are in a good position because they're ordering significant numbers of many of the same products and it's in our mutual interests to get the virus under control. The more products the better as there's a likelihood we could all be scraping around in 12-24 months for additional doses.
|
Indeed - they have access to the same data as us, the same level of expertise and a similar assessment of risk. Where there are differences in our portfolios, that really just is the result of the inevitable gambling component of a situation like this. It’s why there’s even a portfolio in the first place and not just an order for one vaccine from one manufacturer.
The EU plausibly has a price per unit advantage if it is able to put down significantly larger orders, but given that no vaccines have yet been produced, demand massively outstrips supply and the politics of where vaccines are being developed and manufactured also plays a part, that’s by no means guaranteed.
What interests me most here is the EU’s internal politics. Who pays for the vaccine and who gets it first? From what I’ve read so far, it isn’t likely to be down to plain and simple pooling and sharing.